Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Pavankumar Rudrabhatla"'
Autor:
Pavankumar Rudrabhatla, Sekar Sabarish, Sruthi S Nair, Tobin George, Ganesh Divakar, P N Sylaja
Publikováno v:
Annals of Indian Academy of Neurology, Vol 25, Iss 1, Pp 156-157 (2022)
Externí odkaz:
https://doaj.org/article/099dbd476a6e4b79b58bdc91127e607f
Autor:
Pavankumar Rudrabhatla, Surendran Deepanjali, Jharna Mandal, Rathinam Palamalai Swaminathan, Tamilarasu Kadhiravan
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0197302 (2018)
OBJECTIVE:To evaluate whether stopping the effective antibiotic treatment following clinical improvement at Day 7 (Truncated treatment) would be non-inferior to continued treatment until Day 14 (Continued treatment) in patients with acute pyelonephri
Externí odkaz:
https://doaj.org/article/5a31109caa3e4363b1297c6f870c69ad
Autor:
Sabarish Sekar, Bejoy Thomas, Vinayagamani Selvadasan, Chandrasekharan Kesavadas, Pavankumar Rudrabhatla
Publikováno v:
Neurology. 96(19)
A 10-month-old boy, born of nonconsanguineous parents, without any perinatal insult, presented with tonic spasms from the 13th day of life. He started having tonic seizures from 4 months of age, with global developmental delay. On examination, there
Publikováno v:
Neurology. 96(20)
A 34-year-old woman presented with a 1-year history of progressive apathy, executive dysfunction, and memory impairment. Examination revealed moderate frontal dysfunction and bipyramidal signs. MRI brain (figure 1) showed a symmetric leukoencephalopa
Publikováno v:
Neuroimmunology Reports. 2:100060
Autor:
Sekar Sabarish, Tobin George, Ganesh Divakar, SruthiS Nair, Pavankumar Rudrabhatla, P N Sylaja
Publikováno v:
Annals of Indian Academy of Neurology. 25:156
Autor:
Tamilarasu Kadhiravan, Jharna Mandal, Pavankumar Rudrabhatla, Rathinam Palamalai Swaminathan, Surendran Deepanjali
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0197302 (2018)
PLoS ONE
PLoS ONE
Objective To evaluate whether stopping the effective antibiotic treatment following clinical improvement at Day 7 (Truncated treatment) would be non-inferior to continued treatment until Day 14 (Continued treatment) in patients with acute pyelonephri